![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
The item has been added to your shopping cart.
Home » Janssen Schizophrenia Drug Aces Phase III Trial
Janssen Schizophrenia Drug Aces Phase III Trial
![](https://www.fdanews.com/ext/resources/test/Drug-Images/Colored-Cylinders.gif?t=1434716190&width=430)
An independent data monitoring committee has stopped a Phase III trial of a schizophrenia drug developed by Janssen early after the treatment showed statistically significant results in delaying the time to relapse, the Johnson & Johnson subsidiary said Thursday.
The international, randomized and double-blind study evaluated a three-month formulation of paliperidone palmitate in patients whose schizophrenia had appeared more than one year prior to the start date of April 2012.
A one-month formulation of the drug is already approved by the FDA as a maintenance treatment of schizophrenia.
Janssen hopes that a final analysis of study results, along with discussions with the FDA, will support a late-2014 NDA submission. — Lena Freund
Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.
Upcoming Events
-
18Jul
-
21Oct